Libre Life aims to ensure factual accuracy in its editorial content.
We cover diabetes medtech, CGM developments, hybrid-closed loop systems, insulin pump technology, product announcements, regulatory developments and practical real-world device use.
Technology timelines, product specifications, regulatory approvals and commercial plans can change. Where new information becomes available, we may update articles to reflect the latest information.
If a factual error is identified, we aim to review it and make corrections where appropriate.
This may include:
Material corrections may be reflected within the article.
Minor edits for clarity, formatting or readability may be made without a specific correction notice.
Some Libre Life content includes editorial analysis, commentary and opinion.
Corrections relate to factual accuracy rather than editorial interpretation or opinion.
If you believe an article contains a factual error, please contact us with:
Correction requests can be submitted via our contact page:
https://lovemylibre.com/pages/contact
Libre Life is published by Love My Libre Ltd.
Editorial content is reviewed and updated in line with our editorial standards where appropriate.
For further information, please see our Editorial Policy.